Third Quarter 2024 Financial Results Cash, cash equivalents, and investments as of September 30, 2024, were approximately $19.7 million. The Company anticipates that its cash, cash equivalents and ...

DelveInsight's Dermatological Drugs Market Insights report provides the current and forecast market analysis, individual ...

Empire Petroleum Corp (EP) is expected to report for 3Q. F&M Bank Corp (FMBM) is expected to report for 3Q. Galectin Therapeutics Inc (GALT) is expected to report for 3Q. Gyrodyne LLC (GYRO) is ...